Evidence map›Paper›PMID 42179676›Full record

ArticleMolecular therapy. Advances2026

Efficient, fratricide free non-viral engineering of CD70-targeted CAR NK cells for hematologic and solid tumor immunotherapy.

Jae-Woong Chang, Joshua Krueger, Timothy D Folsom, Joseph G Skeate, Erin M Stelljes, Walker S Lahr, Nicholas J Slipek, Emily J Pomeroy, Beau R Webber, Branden S Moriarity

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy. Advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Jae-Woong ChangDepartment of Pediatrics, University of Minnesota, Minneapolis, MN, USA.
Joshua KruegerDepartment of Pediatrics, University of Minnesota, Minneapolis, MN, USA.
Timothy D FolsomDepartment of Pediatrics, University of Minnesota, Minneapolis, MN, USA.
Joseph G SkeateDepartment of Pediatrics, University of Minnesota, Minneapolis, MN, USA.
Erin M StelljesDepartment of Pediatrics, University of Minnesota, Minneapolis, MN, USA.
Walker S LahrDepartment of Pediatrics, University of Minnesota, Minneapolis, MN, USA.
Nicholas J SlipekDepartment of Pediatrics, University of Minnesota, Minneapolis, MN, USA.
Emily J PomeroyDepartment of Pediatrics, University of Minnesota, Minneapolis, MN, USA.
Beau R WebberDepartment of Pediatrics, University of Minnesota, Minneapolis, MN, USA.
Branden S MoriarityDepartment of Pediatrics, University of Minnesota, Minneapolis, MN, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Natural killer (NK) cells are a component of the innate immune system with potential safety advantages over T cells for adoptive cell therapy (ACT). However, NK cells lack the potency and persistence needed for tumor clearance. Here, we report an efficient and cost-effective non-viral method for engineering CD70 targeted CAR NK cells using a hyperactive

Indexed as

acute myeloid leukemiachimeric antigen receptorCRISPR-Cas9 CD70fratricidenatural killer cellsrenal cell carcinomaTcBuster

Identifiers

PMID42179676
PMCPMC13195327

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.